α-腐殖质,在各种植物的精油中发现的倍半萜,由于其潜在的治疗应用而引起了人们的兴趣。本次范围审查旨在巩固α-胡芦烯的证据基础,为临床翻译提供信息,指导未来的研究方向。对EMBASE进行了范围审查,截至2023年7月14日的MEDLINE和PubMed数据库。所有描述α-腐植烯提取原始研究的研究,纳入临床前和临床研究进行回顾.分析了三百四十篇文章。在植物物种中,α-腐殖质的产量范围从微不足道到60.90%。体外实验证明了对腺癌的细胞毒性(例如结直肠,肺,乳房,前列腺,肺,和卵巢),在其他细胞模型中具有不同的反应机制见解揭示了其参与线粒体功能障碍,细胞内谷胱甘肽水平降低,和氧化应激的诱导。在啮齿动物研究中,口服50mg/kgα-humulene可减少爪水肿和卵清蛋白诱导的气道炎症中的炎症标志物。腹膜内施用α-腐植烯(50-200mg/kg)通过大麻素1和腺苷A2a受体表现出大麻模拟特性。α-humulene还表现出多种特性,具有潜在的治疗用途。然而,很少有研究成功地将这项研究转化为相关疾病的临床人群。确定了临床翻译的潜在障碍,包括产量变异性,有限的隔离研究,以及与萜烯生物利用度相关的挑战。因此,严格的药代动力学研究和进一步的机理研究是必要的,以有效地揭示α-腐殖烯的潜力。
α-humulene, a sesquiterpene found in essential oils of various plant species, has garnered interest due to its potential therapeutic applications. This scoping review aims to consolidate α-humulene\'s evidence base, informing clinical translation, and guiding future research directions. A scoping review was conducted of EMBASE, MEDLINE, and PubMed databases up to 14th July 2023. All studies describing original research on α-humulene extraction, as well as pre-clinical and clinical research, were included for review. Three hundred and forty articles were analysed. α-humulene yields ranged from negligible to 60.90% across plant species. In vitro experiments demonstrated cytotoxicity against adenocarcinomas (such as colorectal, pulmonary, breast, prostatic, lung, and ovarian), with varying responses in other cell models. Mechanistic insights revealed its involvement in mitochondrial dysfunction, diminished intracellular glutathione levels, and the induction of oxidative stress. In rodent studies, oral administration of α-humulene at 50 mg/kg reduced inflammation markers in paw oedema and ovalbumin-induced airway inflammation. Intraperitoneal administration of α-humulene (50 - 200 mg/kg) exhibited cannabimimetic properties through cannabinoid 1 and adenosine A2a receptors. α-humulene also exhibited a multitude of properties with potential scope for therapeutic utilisation. However, there is a paucity of studies that have successfully translated this research into clinical populations with the associated disease. Potential barriers to clinical translation were identified, including yield variability, limited isolation studies, and challenges associated with terpene bioavailability. Consequently, rigorous pharmacokinetic studies and further mechanistic investigations are warranted to effectively uncover the potential of α-humulene.